Evaluating the safety and effects of GL-0719 in healthy adults and patients with cold agglutinin disease

GL-0719 - A Phase 1, Double-blind, Placebo-controlled, Single Ascending Intravenous and Subcutaneous Injection Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and an Open-label Evaluation of Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease

This study is testing a new drug called GL-0719 to see if it's safe and effective for both healthy adults and people with cold agglutinin disease.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 70 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Gliknik Inc. (Industry-sponsored)
• Locations: 1 site (Leeds)
• Trial ID: NCT05318534 on ClinicalTrials.gov

What this trial studies

This first-in-human study aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of GL-0719 through both intravenous and subcutaneous administration in healthy adult participants. Additionally, it will evaluate the same parameters in individuals diagnosed with cold agglutinin disease. The study will involve multiple cohorts to ensure a comprehensive understanding of the drug's effects across different populations. Participants will be monitored for any adverse reactions and changes in biomarkers related to efficacy.

Who should consider this trial

Good fit: Ideal candidates include healthy adults aged 18 to 65 and individuals diagnosed with cold agglutinin disease.

Not a fit: Patients who are pregnant, lactating, or have significant health issues outside the eligibility criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to a new treatment option for patients suffering from cold agglutinin disease.

How similar studies have performed: While this is a first-in-human study, similar approaches in evaluating new treatments for complement-mediated diseases have shown promise in other contexts.

Eligibility criteria

Inclusion Criteria for Cohorts 1 to 7

1. Healthy female or male subjects who, at the time of screening, are between the ages of 18 and 65 years, inclusive.
2. Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception.
3. Body mass index of 18.0 to 32.0 kg/m\^2, inclusive; and a total body weight \> 50 kg up to a maximum of 110 kg.
4. Study subjects must have received a quadrivalent meningococcal conjugate vaccine (meningococcal serogroups A, C, W, and Y) within the past 5 years or vaccination a minimum of 14 days prior to initial study drug administration.
5. The subject must be capable of understanding the investigational nature, potential risks and benefits of the study and capable of providing valid informed consent.

Inclusion Criteria for Cohorts 8 to 9

1. Female or male subjects who, at the time of screening, are at least 18 years of age with a total body weight of ≥ 50 kg.
2. Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception.
3. The subject must be capable of understanding the investigational nature, potential risks and benefits of the study and capable of providing valid informed consent.
4. The subject must be willing to return to the study center for study treatment and study-related follow-up procedures as required by the protocol.
5. Study subjects must have received a quadrivalent meningococcal conjugate vaccine (meningococcal serogroups A, C, W, and Y) within the past 5 years or vaccination a minimum of 14 days prior to initial study drug administration.
6. The Participant Identification Center (PIC) site will have provided evidence that the PIC site used to confirm diagnosis of Cold Agglutinin Disease (CAD)
7. Primary Cold Agglutinin Disease (CAD) or CAD secondary to active lymphoid or other hematologic malignancy (Cold Agglutinin Syndrome).
8. Hemoglobin level \< 105 gram per liter (g/L).
9. Bilirubin level above the normal reference range.

Key Exclusion Criteria for Cohorts 1 to 7

1. History of any clinically significant (as determined by the investigator) cardiac, endocrine, hematological, hepatic, immunological, metabolic, urological, pulmonary, neurological, dermatological, psychiatric, renal, or other major disease.
2. Evidence of clinically significant medical condition or other condition that might significantly interfere with the absorption, distribution, metabolism, or excretion of study drug, or place the subject at an unacceptable risk as a participant in this study.
3. Signs and symptoms of, or diagnosis consistent with a chronic autoimmune disorder and/or positive antinuclear antibodies (ANA) test by indirect immunofluorescence confirmed by ANA titer ≥ 1:160.
4. Documented history of autoimmune disease, or history of a syndrome that required systemic steroids or immunosuppressive medications, except for subjects with vitiligo or resolved childhood asthma/atopy.
5. Any underlying medical condition that, in the opinion of the investigator, renders the subject a poor candidate for this study or could confound the results of the study or put the subject at undue risk.

Key Exclusion Criteria for Cohorts 8 to 9

1. CAD secondary to infection or an autoimmune disorder.
2. CAD secondary to active lymphoid or other hematologic malignancy not meeting the inclusion criteria.
3. Diagnosis of any other malignancy except for adequately treated basal or squamous cell skin cancer, curatively treated in situ disease, or other cancer from which the subject has been disease-free for ≥ 5 years.
4. Clinically relevant infection of any kind within the month preceding enrollment (example, active hepatitis C, pneumonia).
5. Clinical diagnosis of Systemic Lupus Erythematosus (SLE), other autoimmune disorders, or ANA titer \> 1:160 at Screening.
6. Positive hepatitis panel and/or positive HIV (Human Immuno Deficiency) test. Subjects whose results are compatible with prior immunization may be included at the discretion of the investigator.
7. Positive HIV antibody at Screening.
8. Treatment with an investigational drug within 90 days or five half-lives preceding the first dose of IP (whichever is longer), with the exception of subjects who received GL-0719 in this study in Cohort 8, who cannot be re-enrolled in Cohort 9 within 60 days after their last dose of GL-0719.
9. Concurrent plasma exchange therapy.

Other protocol defined inclusion/exclusion criteria may apply.

Where this trial is running

Leeds

• Fortrea Clinical Research Unit Ltd — Leeds, United Kingdom (Recruiting)

Study contacts

• Principal investigator: Jim Bush, MBChB, PhD — Fortrea Clinical Research Unit Ltd.
• Study coordinator: Gliknik Clinical Trials Group

Conditions First in Man Study to Evaluate Initial Safety; complement-mediated diseases